sepsis P3 full data in q4 2022 has been mentioned
with interim data late in q4 2021. (See the pre covid presentation attached).
q3 2021 will have interim data on P2b, says another (post covid) presentation.
They are running a lot of studies in semi-parallell so my guess is there will be many news driving this stock.
Covid study news within 6 months, was stated in Jerusalem Post yesterday. So lets call that q3 2021. Additional transplant/GVHD data in q2/q3 2021.